Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2018

ABSTRACT

1. Objectives: Evaluation of mesenchymal stem cell therapy effects on cellular and humoral immune responses in refractory rheumatoid arthritis (RA) patients. 2. Design: This study has been performed as a phase 1 clinical trial. 3. Setting and conduct: Autologous bone marrow derived mesenchymal stem cells were obtained by bone marrow aspiration and cultured in Minimum Essential Medium-Alpha (MEM-alpha) for 4 weeks in standard clean room and then transfused to RA patients intravenously. 4. Participant's major eligibility criteria is as follows: Ten refractory rheumatoid arthritis patients who show resistance to non biological Disease-modifying antirheumatic drugs (DMARDs) after 6 to 12 months have been enrolled in this study. 5. Intervention: A single dose of intravenous autologous bone marrow derived mesenchymal stem cells have been administered into patients with resistance to non-biological DMARDs. 6. Main outcome measures (variables): Finding of mesenchymal stem cell therapy effects on the cellular and humoral immune responses and evaluation of the effect of chemokines in homing of immune cells following the intervention. Detailed Description Refractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been selected. After signing informed consent form, autologous stem cells were obtained by bone marrow aspiration. Isolation and culture (3 to 4 weeks in MEM-alpha medium) of mesenchymal stem cells (MSCs) were performed in accredited good manufacturing practices (GMP) clean room. A panel of cluster of differentiation (CD) markers including CD105, CD166, CD44, CD45, CD90, and CD34 were checked for making sure about differentiation of cells into MSCs after 3-4 weeks of cell culture. Viability of MSCs was checked by Trypan blue testing and all of the cultivations were negative for bacterial contamination. A single dose of 1000000 to 2000000 mesenchymal stem cells/kg infused into patients intravenously. To prevent anaphylactic reactions, a single intravenous dose of hydrocortison (100 ml) and oral dimenhydrinate (10 ml) were administered before MSCs infusion into patients. The effects of mesenchymal stem cells on the cellular and humoral immune responses and also the role of chemokines in homing of immune cells were studied at time points 1, 6 and 12 months after intravenous administration of MSCs in refractory rheumatoid arthritis. More... »

URL

https://clinicaltrials.gov/show/NCT03333681

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "1. Objectives: Evaluation of mesenchymal stem cell therapy effects on cellular and humoral immune responses in refractory rheumatoid arthritis (RA) patients. 2. Design: This study has been performed as a phase 1 clinical trial. 3. Setting and conduct: Autologous bone marrow derived mesenchymal stem cells were obtained by bone marrow aspiration and cultured in Minimum Essential Medium-Alpha (MEM-alpha) for 4 weeks in standard clean room and then transfused to RA patients intravenously. 4. Participant's major eligibility criteria is as follows: Ten refractory rheumatoid arthritis patients who show resistance to non biological Disease-modifying antirheumatic drugs (DMARDs) after 6 to 12 months have been enrolled in this study. 5. Intervention: A single dose of intravenous autologous bone marrow derived mesenchymal stem cells have been administered into patients with resistance to non-biological DMARDs. 6. Main outcome measures (variables): Finding of mesenchymal stem cell therapy effects on the cellular and humoral immune responses and evaluation of the effect of chemokines in homing of immune cells following the intervention.\n\nDetailed Description\nRefractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been selected. After signing informed consent form, autologous stem cells were obtained by bone marrow aspiration. Isolation and culture (3 to 4 weeks in MEM-alpha medium) of mesenchymal stem cells (MSCs) were performed in accredited good manufacturing practices (GMP) clean room. A panel of cluster of differentiation (CD) markers including CD105, CD166, CD44, CD45, CD90, and CD34 were checked for making sure about differentiation of cells into MSCs after 3-4 weeks of cell culture. Viability of MSCs was checked by Trypan blue testing and all of the cultivations were negative for bacterial contamination. A single dose of 1000000 to 2000000 mesenchymal stem cells/kg infused into patients intravenously. To prevent anaphylactic reactions, a single intravenous dose of hydrocortison (100 ml) and oral dimenhydrinate (10 ml) were administered before MSCs infusion into patients. The effects of mesenchymal stem cells on the cellular and humoral immune responses and also the role of chemokines in homing of immune cells were studied at time points 1, 6 and 12 months after intravenous administration of MSCs in refractory rheumatoid arthritis.", 
    "endDate": "2018-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03333681", 
    "keywords": [
      "Evaluation Study as Topic", 
      "mesenchymal stem cell therapy", 
      "Humoral Immunity", 
      "chemokines", 
      "immune cell", 
      "rheumatoid arthritis patient", 
      "cellular and humoral immune response", 
      "rheumatoid arthritis", 
      "patient", 
      "Phase I clinical trial", 
      "setting", 
      "bone marrow-derived mesenchymal stem cell", 
      "bone marrow aspiration", 
      "medium", 
      "alpha", 
      "room", 
      "eligibility criterion", 
      "resistance", 
      "disease", 
      "intervention", 
      "single dose", 
      "main outcome measure", 
      "variable", 
      "homing", 
      "inclusion/exclusion criterion", 
      "consent form", 
      "autologous stem cell", 
      "isolation", 
      "culture", 
      "Mesenchymal Stromal Cell", 
      "Good Manufacturing Practices", 
      "panel", 
      "cluster", 
      "marker", 
      "cell", 
      "Cell Culture Technique", 
      "viability", 
      "cultivation", 
      "bacterial contamination", 
      "anaphylaxis", 
      "single intravenous dose", 
      "Dimenhydrinate", 
      "stem cell", 
      "Time", 
      "intravenous administration"
    ], 
    "name": "Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis Patients", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03333681"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00025.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.411583.a", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s10067-011-1816-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017096260", 
          "https://doi.org/10.1007/s10067-011-1816-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2015-208918", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051878541"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/scd.2013.0023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059310778"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/scd.2013.0023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059310778"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03333681"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03333681'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03333681'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03333681'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03333681'


 

This table displays all metadata directly associated to this object as RDF triples.

74 TRIPLES      16 PREDICATES      63 URIs      54 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03333681 schema:about anzsrc-for:3053
2 schema:description 1. Objectives: Evaluation of mesenchymal stem cell therapy effects on cellular and humoral immune responses in refractory rheumatoid arthritis (RA) patients. 2. Design: This study has been performed as a phase 1 clinical trial. 3. Setting and conduct: Autologous bone marrow derived mesenchymal stem cells were obtained by bone marrow aspiration and cultured in Minimum Essential Medium-Alpha (MEM-alpha) for 4 weeks in standard clean room and then transfused to RA patients intravenously. 4. Participant's major eligibility criteria is as follows: Ten refractory rheumatoid arthritis patients who show resistance to non biological Disease-modifying antirheumatic drugs (DMARDs) after 6 to 12 months have been enrolled in this study. 5. Intervention: A single dose of intravenous autologous bone marrow derived mesenchymal stem cells have been administered into patients with resistance to non-biological DMARDs. 6. Main outcome measures (variables): Finding of mesenchymal stem cell therapy effects on the cellular and humoral immune responses and evaluation of the effect of chemokines in homing of immune cells following the intervention. Detailed Description Refractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been selected. After signing informed consent form, autologous stem cells were obtained by bone marrow aspiration. Isolation and culture (3 to 4 weeks in MEM-alpha medium) of mesenchymal stem cells (MSCs) were performed in accredited good manufacturing practices (GMP) clean room. A panel of cluster of differentiation (CD) markers including CD105, CD166, CD44, CD45, CD90, and CD34 were checked for making sure about differentiation of cells into MSCs after 3-4 weeks of cell culture. Viability of MSCs was checked by Trypan blue testing and all of the cultivations were negative for bacterial contamination. A single dose of 1000000 to 2000000 mesenchymal stem cells/kg infused into patients intravenously. To prevent anaphylactic reactions, a single intravenous dose of hydrocortison (100 ml) and oral dimenhydrinate (10 ml) were administered before MSCs infusion into patients. The effects of mesenchymal stem cells on the cellular and humoral immune responses and also the role of chemokines in homing of immune cells were studied at time points 1, 6 and 12 months after intravenous administration of MSCs in refractory rheumatoid arthritis.
3 schema:endDate 2018-12-01T00:00:00Z
4 schema:keywords Cell Culture Technique
5 Dimenhydrinate
6 Evaluation Study as Topic
7 Good Manufacturing Practices
8 Humoral Immunity
9 Mesenchymal Stromal Cell
10 Phase I clinical trial
11 Time
12 alpha
13 anaphylaxis
14 autologous stem cell
15 bacterial contamination
16 bone marrow aspiration
17 bone marrow-derived mesenchymal stem cell
18 cell
19 cellular and humoral immune response
20 chemokines
21 cluster
22 consent form
23 cultivation
24 culture
25 disease
26 eligibility criterion
27 homing
28 immune cell
29 inclusion/exclusion criterion
30 intervention
31 intravenous administration
32 isolation
33 main outcome measure
34 marker
35 medium
36 mesenchymal stem cell therapy
37 panel
38 patient
39 resistance
40 rheumatoid arthritis
41 rheumatoid arthritis patient
42 room
43 setting
44 single dose
45 single intravenous dose
46 stem cell
47 variable
48 viability
49 schema:name Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis Patients
50 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03333681
51 schema:sdDatePublished 2019-03-07T15:27
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher Nd3af883ba1144cf892d1165bc15a6cdd
54 schema:sponsor https://www.grid.ac/institutes/grid.411583.a
55 schema:startDate 2016-06-01T00:00:00Z
56 schema:subjectOf sg:pub.10.1007/s10067-011-1816-0
57 https://doi.org/10.1089/scd.2013.0023
58 https://doi.org/10.1136/annrheumdis-2015-208918
59 schema:url https://clinicaltrials.gov/show/NCT03333681
60 sgo:license sg:explorer/license/
61 sgo:sdDataset clinical_trials
62 rdf:type schema:MedicalStudy
63 Nd3af883ba1144cf892d1165bc15a6cdd schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
66 rdf:type schema:DefinedTerm
67 sg:pub.10.1007/s10067-011-1816-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017096260
68 https://doi.org/10.1007/s10067-011-1816-0
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1089/scd.2013.0023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059310778
71 rdf:type schema:CreativeWork
72 https://doi.org/10.1136/annrheumdis-2015-208918 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051878541
73 rdf:type schema:CreativeWork
74 https://www.grid.ac/institutes/grid.411583.a schema:Organization
 




Preview window. Press ESC to close (or click here)


...